AlanLohHoMD

Instructor, Medicine, Weill Cornell Medical College

Overview of Dr. Ho

Dr. Alan Ho is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Washington University in St. Louis School of Medicine and has been in practice 14 years. Dr. Ho accepts several types of health insurance, listed below. He is one of 464 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
Memorial Sloan Kettering Cancer Center New York
1275 York Avenue
New York, NY 10021
Book by Phone+1(240) 317-3880
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2009
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2003 - 2006
Washington University in St. Louis School of MedicineClass of 2003

Certifications & Licensure

NJ State Medical License 2019 - 2025
NY State Medical License 2004 - 2024
American Board of Internal Medicine Medical Oncology

Clinical Trials

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244 Start of enrollment: 2009 Sep 01
Completed
Not Applicable
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) Start of enrollment: 2010 Aug 01
Completed
Phase 2
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Start of enrollment: 2012 Mar 01
Completed
Phase 2
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer Start of enrollment: 2015 Sep 24
Active, not recruiting
Phase 2
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Start of enrollment: 2014 Mar 01
Active, not recruiting
Phase 2
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study Start of enrollment: 2014 May 01
Active, not recruiting
Not Applicable
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Start of enrollment: 2014 Aug 14
Active, not recruiting
Phase 2
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma Start of enrollment: 2016 May 19
Active, not recruiting
Phase 2
New MRI Biomarkers in Head and Neck Cancers Start of enrollment: 2018 Mar 16
Recruiting
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Start of enrollment: 2020 Jun 02
Recruiting
Phase 2
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Start of enrollment: 2020 Sep 02
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Start of enrollment: 2020 Jun 26
Completed
Phase 1
Roles: Principal Investigator, Contact
A Study of Avutometinib and Defactinib in People With Thyroid Cancer Start of enrollment: 2023 Aug 16
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers Start of enrollment: 2023 Jul 20
Recruiting
Phase 2
Roles: Contact, Principal Investigator
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer Start of enrollment: 2023 Feb 07
Recruiting
Roles: Contact
Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 Start of enrollment: 2023 Mar 08
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma.
Suzanne Dufault, Audrey A Humphries, Carter Hultman, Ming Lian, P Daniel Knott, Christopher A Barker, Sarah T Arron, Alan L Ho, Alain P Algazi, Lara A Dunn, Sue S Yom> ;Journal of Clinical Oncology. 2024 Apr 17
1 citations
Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma.
Lee, N., Sherman, E., Schöder, H., Wray, R., Boyle, J., Singh, B., Grkovski, M., Paudyal, R., Cunningham, L., Zhang, Z., Hatzoglou, V., Katabi, N., Diplas, B., Han, J....> ;Journal of Clinical Oncology. 2024 Mar 10
Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.
Jagadeeshan, S., Suryamohan, K., Shin, N., Mathukkada, S., Boyko, A., Melikhova, D., Tsareva, A., Yunusova, L., Pravdivtseva, E., Stupichev, D., Shaposhnikov, K., Pete...> ;Oral Oncology. 2024 Feb 1
1 citations
NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024.
Chrysalyne D Schmults, Rachel Blitzblau, Sumaira Z Aasi, Murad Alam, Arya Amini, Kristin Bibee, Diana Bolotin, Jeremy Bordeaux, Pei-Ling Chen, Carlo M Contreras, Domin...> ;Journal of the National Comprehensive Cancer Network. 2024 Jan 1
A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104).
Alan L Ho, Nathan R Foster, Shyamprasad Deraje Vasudeva, Nora Katabi, Cristina R Antonescu, Gary P Frenette, David G Pfister, Charles Erlichman, Schwartz, G.> ;Cancer. 2024 Mar 1
2 citations
Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma.
Cristina Valero, Mahdi Golkaram, Joris L Vos, Bin Xu, Conall Fitzgerald, Mark Lee, Shannon Kaplan, Catherine Y Han, Xin Pei, Reith Sarkar, Lillian A Boe, Abhinav Pande...> ;The Journal of Clinical Investigation. 2023 Oct 2
Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dos...
Lisa Bodei, R Michael Tuttle, Ravinder K Grewal, Audrey Mauguen, Finn Augensen, Murad Abusamra, Sonia Mahajan, Vetri Sudar Jayaprakasam, Joseph R Osborne, Sofia Haque,...> ;European Journal of Nuclear Medicine and Molecular Imaging. 2024 Jan 1
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Glenn J Hanna, Myung-Ju Ahn, Jameel Muzaffar, Bhumsuk Keam, Daniel W Bowles, Deborah J Wong, Alan L Ho, Sung-Bae Kim, Francis Worden, Tak Yun, Xianzhang Meng, Jan M Va...> ;Clinical Cancer Research. 2023 Nov 14
7 citations
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.
Joris L Vos, Bharat Burman, Swati Jain, Conall W R Fitzgerald, Eric J Sherman, Lara A Dunn, James V Fetten, Loren S Michel, Anuja Kriplani, Kenneth K Ng, Juliana Eng, ...> ;Nature Medicine. 2023 Dec 1
1 citations
The evolving landscape of salivary gland tumors.
Conor E Steuer, Glenn J Hanna, Kartik Viswanathan, James E Bates, Azeem S Kaka, Nicole C Schmitt, Alan L Ho, Nabil F Saba> ;CA. 2023 Jul 25
Cooperative Genomic Lesions in HRAS-Mutant Cancers Predict Resistance to Farnesyltransferase Inhibitors.
Aradhya Nigam, Gnana Krishnamoorthy, Walid Chatila, Katherine Berman, Mahesh Saqcena, Henry Walch, Alan Ho, Nikolaus Schultz, James Fagin, Brian Untch> ;Research Square. 2023 Jul 14
5 citations
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
Alison E Smith, Stacia Chan, Zhiyong Wang, Asako McCloskey, Quinn Reilly, Jayden Z Wang, Hetika Vora Patel, Keiichi Koshizuka, Harris S Soifer, Linda Kessler, Ashley D...> ;Cancer Research. 2023 Oct 2
2 citations
The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction ...
Audrey Mauguen, Ravinder K Grewal, Finn Augensen, Murad Abusamra, Sonia Mahajan, Vetri Sudar Jayaprakasam, Joseph Osborne, Sofia Haque, Bernadette Z Y Wong, Ronald A G...> ;European Journal of Nuclear Medicine and Molecular Imaging. 2023 Aug 1
1 citations
Loss of CDKN2A/B is a Molecular Marker of High-grade Histology and is Associated with Aggressive Behavior in Acinic Cell Carcinoma.
Snjezana Dogan, Bin Xu, Satshil Rana, Hui Chen, Ronald A Ghossein, Michael F Berger, Alan L Ho, Nora Katabi> ;Modern Pathology. 2023 Jul 1
4 citations
Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy.
Laura Boucai, Mahesh Saqcena, Fengshen Kuo, Ravinder K Grewal, Nicholas Socci, Jeffrey A Knauf, Gnana P Krishnamoorthy, Mabel Ryder, Alan L Ho, Ronald A Ghossein, Luc ...> ;Clinical Cancer Research. 2023 Apr 14
3 citations
Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer.
Sankar Jagadeeshan, Manu Prasad, Mai Badarni, Talal Ben-Lulu, Vijayasteltar Belsamma Liju, Sooraj Mathukkada, Claire Saunders, Avital Beeri Shnerb, Jonathan Zorea, Kse...> ;Cancer Research. 2023 Apr 4
7 citations
Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma.
Anna Lee, Robbie Woods, Amgad Mahfouz, Sarin Kitpanit, Olivia Cartano, Nader Mohamed, Irini Youssef, Kathryn Marqueen, Kevin Sine, Dennis Mah, Brian Neal, Kaveh Zakeri...> ;JAMA Network Open. 2023 Jan 3
8 citations
Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulate...
Irini Youssef, Jennifer Yoon, Nader Mohamed, Kaveh Zakeri, Robert H Press, Linda Chen, Daphna Y Gelblum, Sean M McBride, Chiaojung Jillian Tsai, Nadeem Riaz, Yao Yu, M...> ;JAMA Network Open. 2022 Nov 1
17 citations
Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer.
Jung Julie Kang, Yao Yu, Linda Chen, Kaveh Zakeri, Daphna Yael Gelblum, Sean Matthew McBride, Nadeem Riaz, C Jillian Tsai, Anuja Kriplani, Tony K W Hung, James V Fette...> ;CA. 2023 Mar 1
2 citations
Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Alan L Ho> ;Journal of Clinical Oncology. 2023 Feb 1
2 citations
Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future Promise.
Antoine Desilets, Alan L Ho> ;Cancer Journal. 2022 Sep 27
13 citations
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).
Alan L Ho, Nathan R Foster, Alex J Zoroufy, Jordan D Campbell, Francis Worden, Katharine Price, Douglas Adkins, Daniel W Bowles, Hyunseok Kang, Barbara Burtness, Eric ...> ;Journal of Clinical Oncology. 2022 Dec 20
9 citations
Head and Neck Acinic Cell Carcinoma: A New Grading System Proposal and Diagnostic Utility of NR4A3 Immunohistochemistry.
Bin Xu, Maelle Saliba, Alan Ho, Kartik Viswanathan, Bayan Alzumaili, Snjezana Dogan, Ronald Ghossein, Nora Katabi> ;The American Journal of Surgical Pathology. 2022 Jul 1
5 citations
ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.
Donna C Ferguson, Amir Momeni Boroujeni, Tao Zheng, Abhinita S Mohanty, Alan L Ho, Maria E Arcila, Dara S Ross, Snjezana Dogan> ;Modern Pathology. 2022 Jul 1
5 citations
A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyr...
Nancy Y Lee, Nadeem Riaz, Vanessa Wu, Thomas Brinkman, Chiaojung J Tsai, Wanquing Zhi, James Fetten, Alan Ho, Richard J Wong, Ronald Ghossein, Michael Tuttle, James Fa...> ;Thyroid. 2022 Jul 1
Join now to see all

Journal Articles

Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
Steven M Larson, Sofia Haque, Duan Li, R Michael Tuttle, Mona M Sabra, Alan L Ho, Eric J Sherman, Ravinder K Grewal, James A Fagin, David G Pfister, Ronald A Ghossein, The Journal of Clinical Endocrinology and Metabolism
Multi-Dimensional Genomic Analysis of Myoepithelial Carcinoma Identifies Prevalent Oncogenic Gene Fusions
Ian Ganly, Alan L Ho, Ronald Ghossein, Nadeem Riaz, Cristina R Antonescu, Nora Katabi, Nature

Lectures

Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Long-Term Follow-up Confirms Pembrolizumab and Pembrolizumab-Chemotherapy as Effective First-Line Treatment Options for Recurrent or Metastatic HNSCCOctober 14th, 2022
Enzalutamide in Advanced Androgen Receptor-Positive Salivary Gland CancerAugust 4th, 2022
Abiraterone Active in Androgen Receptor-Positive Salivary TumorsOctober 14th, 2021
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Memorial Sloan Kettering Cancer CenterNew York, New York

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment